Annals of internal medicine

Changing reasons for prescribing GLP-1 receptor agonists across the country

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M24-0019.
PubMed

Related papers

Aug '25
Changes in prescribing patterns of drugs that activate the glucagon-like peptide 1 receptor
top 30% journal
cited by 26 papers
observational study
Jul '25
Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in South Korean Patients with Type 2 Diabetes and Heart Disease
top 20% journal
cited by 3 papers
journal article
Aug '24
Use of newer blood sugar medicines over time in US adults with type 2 diabetes and heart disease or heart failure from 2005 to 2019
top 30% journal
cited by 2 papers
research support, n.i.h., extramural
Feb '17
Treatment use in type 2 diabetes patients using GLP-1 medicines: Higher adherence and continued use with dulaglutide compared to once-weekly exenatide and liraglutide
cited by 101 papers
observational study

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
6 days ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
1 week ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
2 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
3 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
4 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
5 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
6 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
7 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
8 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief